INCIDENCE OF ENDOMETRIAL HYPERPLASIA IN 100 CASES PRESENTING WITH POLYMENORRHAGIA/MENORRHAGIA IN PERIMENUPAUSAL WOMEN

Authors

  • Amera Takreem
  • Nargis Danish
  • Sadia Razaq

Abstract

Background: To study the Incidence of endometrial hyperplasia in perimenupausal women presentingwith polymenorrhagia/menorrhagia. This observational study was conducted at Gynae ‘B’ unit ofKhyber Teaching Hospital Peshawar from January 2000 to December 2001. Methods: One hundredconsecutive patients who presented at Gynaecology OPD with Polymenorrhagia/ Menorrhagia wereregistered and incidence of endometrial hyperplasia evaluated in them. All women were above 45 yearsof age. Post-menopausal bleeding cases were excluded from the study. Results: Out of 100 patients, 15patients were found to have endometrial hyperplasia, 10 patients (66.6%) simple cystic hyperplasia, 3patients (20.0%) had adenomotous hyperplasia, 2 patients (13.3%) had atypical hyperplasia, 8 patients(53.3%) with menorrhagia, 1 (6.6%) with polymenorrhagia, and 6 patients (40.0%) withpolymenorrhoea. Duration of symptoms was from 4 months to 1 year. Thirteen (86.6%) patients weretreated medically, 5 patients (33.33%) needed surgical treatment following medical treatment, 2patients (13.3%) underwent Total Abdominal Hysterectomy (TAH) and Bilateral Salpingooophorectomy (BSO) who were 51–53 years of age with atypical hyperplasia. Conclusion:endometrial hyperplasia is a pre-malignant condition; if treated in time, incidence can be reduced andearly treatment can increase life expectancy and quality in women over age of 45 years.Keyword: Menorrhagia, Polymenorrhagia, Endometrial hyperplasia, Transvaginal Ultrasound, TVS

References

Kurman RJ, Kamiriski PF, Norris HJ. The behavior of

endometrial hyperplasia; A long term study of untreated

endometrial hyperplasia in 170 patients. Cancer

;56:403–12.

Wentz WB. Progestin therapy in endometrial hyperplasia.

Gynaecol Oncol 1974;2:362–7.

Mishal DR, Droegmuller-W, Merbot-AL. Abdominal uterine

bleeding. Corhensive Gynaecology. 953–64.

Niwa K, Morishita S, Hashimoto M, Itoh T, Fujimoto J, Mori

H, et al. Effects of tamoxifen on endometrial carcinogenesis

in mice. Jpn J Cancer Res 1998;89(5):502–9.

Fox H, Langley FA. eds. Tumours of ovary. London:

Heinemann Medical;1976. p.119–37.

Tavasolli F, Krawz FT. Endometrial lesions in uteri resected

for atypical endometrial hyperplasia. Am J Clin Pathol

;70:770–9.

Colgan TJ, Norris HJ, Foster W, Kurman RJ, Fox CH..

Predicting the outcome of endometrial hyperplasia by

quantitive analysis of nuclear features using a linear

discriminate function. Int J Gynaecol Pathol 1983;1(4):347–52.

Campbell PE, Barter RA. The significance of atypical

hyperplasia. J Obstet Gynaecol Br Commonw 1961;68:668–72.

Sommers SC. The clinical significance of endometrial

hyperplasia and its early diagnosis. In Barber HRK, Graber

EA (eds): Gynecologic Oncology. Baltimore: Williams &

Wilkins; 1970.

Horbelt DV, Roberts DK, Parmley TH, Walker NJ.

Ultrastructure of the microvasculature in human endometrial

hyperplasia. Am J Obstet Gynecol 1996;174(1 Pt-1):174–83.

Mughal N. Diagnostic Value of endometrial curettage, in

abnormal uterine bleeding. J Pak Med Assoc

;47(12):295–8.

Fayyaz S, Majeed SS. Audit of Gynaecological

hysterectomies. J Postgrad Med Inst 2001;15(2):208–12.

Riffat Jalil. A study to correlate the indication of abdominal

hysterectomy with histopathological findings. 1998. (FCPS

Dissertation).

Adil F. D&C in excessive and abnormal uterine bleeding (2

year study) Obst Gynae B Unit Dow Medical College

Karachi. 1997 (FCPS Dissertation)

Terakawa N, Kigawa J, Taketani Y, Yoshikawa H, Yajima

A, Noda K, et al. The behavior of endometrial hyperplasia: a

prospective study. Endometrial Hyperplasia Study Group. J

Obstet Gynaecol Res 1997;23(3):223–30.

Menwissen JH et al 1996, Endometrial Biopsy the female

patient 1993,4:19–23.

Bakos O, Heimer G. Transvaginal Ultrasonography

evaluation of the endometirum related to the histological

findings in pre-and permenopausal women. Gynaecol Obstet

Invest 1998;45(3):199–204.

el-Ahmady O, Gad M, el-Sheimy R, Halim AB, Eissa

S, Hassan F, et al. Comparitive study between sonography

pathology and UGP in women with periomenopausal

bleeding. Anticancer Res 1996;16(4B):2309–13.

Ben Yehuda OM, Kim YB, Leuchter RS. Does Hysteroscopy

improve upon the sensitivity of dilatation and curettage in the

diagnosis of endometrial hyperplasia or carcinoma?

Gynaecol Oncol1998;68(1):4–7.

Ho SP, Tan KT, Pang MW, Ho TH. Endometrial hyperplasia

and the risk of endometrial carcinoma. Singapore Med J

;38(1):11–5.

Gücer F, Reich O, Tamussino K, Bader AA, Pieber D, Schöll

W, et al. Concomitant endometrial Hyperplasia in patients with

endometrial carcinoma. Gynaecol Oncol 1998;69(1)64–8.

Colacurci N, De Placido G, Mollo A, Perino A, Cittadini E.

Short term use of Goserlin Depot in the treatment of

dysfunctional uterine bleeding. Clin Exp Obstet

Gynecol 1995;22:212–9.

Gimpalson RJ. Not so benign endometrial hyperplasia:

endometrial cancer after endometrial ablation. J Am Assoc

Gynaecol Laprarosc 1997;4(4):507–11.

Downloads

Published

2009-06-01

Most read articles by the same author(s)